https://ntp.niehs.nih.gov/go/15782

TDMS Study 96020-01 Pathology Tables

NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04
Route: GAVAGE                                                                                                     Time: 13:47:44
                                                     53 WEEK SSAC FINAL #1
       Facility:  Battelle Columbus Laboratory
       Chemical CAS #:  TEFBINARYMIX
       Lock Date:  03/27/02
       Cage Range:  All
       Reasons For Removal:    25017 Scheduled Sacrifice
       Removal Date Range:     09/16/99 - 09/17/99
       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 002    10 NG / 10 UG
                               Include 003    100 NG /100 UG
                               Include 005    300 NG /300 UG
                               Include 007    1000 NG/1000 UG
a  Number of animals examined microscopically at site and number of animals with lesion
                                                              Page   1
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 13:47:44    
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY                                                                                                                 
  Animals Initially In Study                          98           86           98           98           98                        
  Scheduled Sacrifice                                 13           13           13           13           13                        
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         
  Animals Examined Microscopically                     8            8            8            8            8                        
____________________________________________________________________________________________________________________________________
 ALIMENTARY SYSTEM                                                                                                                  
   Liver                                              (8)          (8)          (8)          (8)          (8)                       
      Basophilic Focus                                              3 (38%)      1 (13%)                   1 (13%)                  
      Cholangiofibrosis                                                                                    1 (13%)                  
      Eosinophilic Focus                                                                      1 (13%)                               
      Eosinophilic Focus, Multiple                                                                         7 (88%)                  
      Fatty Change, Diffuse                                                                   3 (38%)      8 (100%)                 
      Fatty Change, Focal                                                                                  1 (13%)                  
      Hyperplasia, Nodular                                                                                 2 (25%)                  
      Infiltration Cellular, Histiocyte                                          1 (13%)      1 (13%)                               
      Inflammation                                     8 (100%)     8 (100%)     8 (100%)     8 (100%)     8 (100%)                 
      Mixed Cell Focus                                 1 (13%)      1 (13%)      4 (50%)                                            
      Mixed Cell Focus, Multiple                       4 (50%)      7 (88%)      2 (25%)      2 (25%)      1 (13%)                  
      Necrosis                                                                                             1 (13%)                  
      Pigmentation                                                  1 (13%)      6 (75%)      8 (100%)     8 (100%)                 
      Toxic Hepatopathy                                                                                    8 (100%)                 
      Bile Duct, Fibrosis                                                                                  1 (13%)                  
      Bile Duct, Hyperplasia                                                                               8 (100%)                 
      Hepatocyte, Hypertrophy                                       2 (25%)      2 (25%)      8 (100%)     8 (100%)                 
      Hepatocyte, Multinucleated                                                              2 (25%)      8 (100%)                 
      Oval Cell, Hyperplasia                                                                               4 (50%)                  
   Pancreas                                           (8)          (8)          (8)          (8)          (8)                       
      Inflammation, Chronic Active                                  1 (13%)                                1 (13%)                  
      Acinus, Atrophy                                               1 (13%)                                1 (13%)                  
      Acinus, Vacuolization Cytoplasmic                                                                    7 (88%)                  
____________________________________________________________________________________________________________________________________
 CARDIOVASCULAR SYSTEM                                                                                                              
   Heart                                                                                                  (1)                       
      Pericardium, Inflammation, Chronic Active                                                            1 (100%)                 
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                             Page    2                                                              
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 13:47:44    
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
 ENDOCRINE SYSTEM                                                                                                                   
   Adrenal Cortex                                     (8)          (8)          (8)          (8)          (8)                       
      Degeneration, Cystic                             2 (25%)      1 (13%)                   1 (13%)                               
      Hyperplasia                                      1 (13%)      4 (50%)      1 (13%)      1 (13%)      1 (13%)                  
      Hypertrophy                                      4 (50%)      4 (50%)      5 (63%)      5 (63%)      2 (25%)                  
      Vacuolization Cytoplasmic                                                  1 (13%)                   1 (13%)                  
   Thyroid Gland                                      (8)          (8)          (8)          (8)          (8)                       
      C-Cell, Hyperplasia                              2 (25%)      1 (13%)                                                         
      Follicular Cell, Hypertrophy                                  2 (25%)      4 (50%)      6 (75%)      4 (50%)                  
____________________________________________________________________________________________________________________________________
 GENERAL BODY SYSTEM                                                                                                                
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 GENITAL SYSTEM                                                                                                                     
   Ovary                                              (8)          (8)          (8)          (8)          (8)                       
      Atrophy                                          7 (88%)      6 (75%)      7 (88%)      7 (88%)      6 (75%)                  
      Cyst                                             1 (13%)                                1 (13%)      1 (13%)                  
   Uterus                                             (8)          (8)          (8)          (8)          (8)                       
      Inflammation, Suppurative                                                                            1 (13%)                  
      Metaplasia, Squamous                             7 (88%)      6 (75%)      7 (88%)      7 (88%)      3 (38%)                  
      Endometrium, Hyperplasia, Cystic                 5 (63%)                                                                      
____________________________________________________________________________________________________________________________________
 HEMATOPOIETIC SYSTEM                                                                                                               
   Spleen                                             (8)                                                                           
      Pigmentation                                     8 (100%)                                                                     
   Thymus                                             (8)          (8)          (8)          (8)          (8)                       
      Atrophy                                          5 (63%)      8 (100%)     8 (100%)     8 (100%)     8 (100%)                 
____________________________________________________________________________________________________________________________________
 INTEGUMENTARY SYSTEM                                                                                                               
   Mammary Gland                                      (8)          (2)                       (5)          (1)                       
      Cyst                                             1 (13%)      2 (100%)                  2 (40%)                               
      Hyperplasia                                      4 (50%)      2 (100%)                  1 (20%)                               
      Inflammation, Granulomatous                                                             1 (20%)                               
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                             Page    3                                                              
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 13:47:44    
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
 MUSCULOSKELETAL SYSTEM                                                                                                             
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 NERVOUS SYSTEM                                                                                                                     
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 RESPIRATORY SYSTEM                                                                                                                 
   Lung                                               (8)          (8)          (8)          (8)          (8)                       
      Hemorrhage                                                                                           1 (13%)                  
      Infiltration Cellular, Histiocyte                4 (50%)      5 (63%)      5 (63%)      2 (25%)      1 (13%)                  
      Alveolar Epithelium, Metaplasia, Bronchiolar                                            1 (13%)      3 (38%)                  
____________________________________________________________________________________________________________________________________
 SPECIAL SENSES SYSTEM                                                                                                              
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 URINARY SYSTEM                                                                                                                     
   None                                                                                                                             
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                             Page    4                                                              
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------